

Lund 5 September 2025

EQL Pharma AB

Reg. No. 556713-3425

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

Exercise of warrants in EQL Pharma AB's incentive programs

EQL Pharma AB (the "Company") today announces that two senior executives and one key employee in the Company have chosen to exercise 466,000 warrants in the Company's outstanding incentive programs for subscription of a total of 466,000 new shares.

The Company's CEO as well as one senior executive and one key employee in the Company have chosen to make full use of the opportunity to subscribe for shares by exercise of warrants in the Company's long-term incentive programs 2021/2025 I and 2021/2021 II, respectively, which were resolved by the annual general meeting in August 2021 and the extraordinary general meeting in December 2021, respectively. A total of 466,000 warrants have been exercised in both programs, each of which entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 72.05 and SEK 67.50, respectively, per share. As a result, the Company will receive approximately SEK 31.8 million in cash.

To finance the share subscription, these warrant holders have sold in total 345,642 shares at a value of approximately SEK 28.0 million. The sale of the shares was carried out through DNB Carnegie Investment Bank (publ) in the market. To facilitate the transaction, one of the Company's major shareholders has lent 345,642 shares in the Company to these warrant holders, who have undertaken to return these shares without delay as soon as practically possible after the share subscription has been registered by the Swedish Companies Registration Office.

The subscription period in the warrant programs runs until 30 September 2025 and participants who have not yet subscribed for shares in accordance with the above can therefore choose to subscribe for additional shares until this date.

For additional information, please contact:

Axel Schörling

President and CEO EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-Mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

The information was submitted for publication, through the agency of the contact person set out above, on 5 September 2025 at 10.00 CEST.

EQL Pharma AB briefly

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.